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Background: Secretory leukocyte protease inhibitor (SLPI) is a protein with anti-protease and antimicrobial properties
that is constitutively secreted from the airway epithelium. The importance of maintaining a balance between proteases
and anti-proteases, and robust innate defence mechanisms in the airways, is exemplified by inflammatory lung
conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Both conditions present with
a high protease burden in the airways which leads to tissue destruction. These patients also have an impaired innate
immune system in the lungs with bacterial colonization and frequent airway infections. Moreover, both diseases are
associated with airway hypoxia due to inflammation and mucus plugs. The aim of the present study was to investigate
the role of hypoxia on SLPI production from the airway epithelium.
Methods: Primary human bronchial epithelial cells were grown in sub-immersed cultures or as differentiated
epithelium in air liquid interface cultures. Cells were incubated at 21% O2 (normoxia) or 1% O2 (hypoxia), and the
release of SLPI was analysed with ELISA. RT-PCR was used to study the expression of SLPI and transforming growth
factor β1 (TGF-β1).
Results: Hypoxia decreased the constitutive production of SLPI by bronchial epithelial cells. The multifunctional
cytokine TGF-β1, which is known to affect SLPI expression, showed increased expression in hypoxic bronchial epithelial
cells. When bronchial epithelial cells were exposed to exogenous TGF-β1 during normoxia, the SLPI production was
down-regulated. Addition of TGF-β1-neutralizing antibodies partially restored SLPI production during hypoxia, showing
that TGF-β1 is an important regulator of SLPI during hypoxic conditions.
Conclusions: The mechanism described here adds to our knowledge of the pathogenesis of severe pulmonary
diseases associated with hypoxia, e.g. COPD and CF. The hypoxic down-regulation of SLPI may help explain the
protease/anti-protease imbalance associated with these conditions and vulnerability to airway infections. Furthermore,
it provides an interesting target for the treatment and prevention of exacerbation in these patients.
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Secretory leukocyte protease inhibitor (SLPI) is a small pro-
tein of 11.7 kDa that is secreted by mucosal linings, includ-
ing the airway epithelium [1]. As the name implies, SLPI
has anti-protease activity and plays an important role in
neutralizing enzymes such as neutrophil elastase in order
to prevent excessive tissue damage during inflammation* Correspondence: lisa.pahlman@med.lu.se
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unless otherwise stated.[2]. Moreover, the protein also possesses antimicrobial ac-
tivity against gram-positive and gram-negative bacteria,
mycobacteria and fungi [3-6], although the mechanisms be-
hind its antimicrobial properties are not fully understood.
Chronic obstructive pulmonary disease (COPD) and cys-
tic fibrosis (CF) are two conditions affecting the lungs.
Although the pathophysiology differs between the two dis-
eases, they have several clinical manifestations in common.
COPD is typically caused by long-term exposure to
cigarette smoke, resulting in deterioration of lung function.
In severe cases, these patients usually require long-termal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hand, is caused by a defect in the CF transmembrane con-
ductance regulator gene, resulting in impaired chloride
transport and excess mucus production [8]. Inflammation
and infection are hallmarks of both diseases, and also major
causes of the deterioration of respiratory function. The
pathogenesis of both conditions is believed to involve a
protease-antiprotease imbalance, where the protease activ-
ity from inflammatory cells is not adequately counter-acted
by anti-proteases [9,10]. Moreover, bacteria often colonize
the lungs of these patients, and they frequently suffer from
airway infections and exacerbation that have profound ef-
fects on morbidity and mortality [11-14]. Given that SLPI
has both antimicrobial and antiprotease properties, regula-
tion of the protein may have important implications for dis-
ease progression.
Transforming growth factor β1 (TGF-β1) is a pleio-
tropic, multifunctional growth factor with fibrogenic and
immunomodulatory properties. The protein has been
implicated as an important regulator in the pathogenesis
of inflammatory pulmonary conditions such as COPD,
and an increase in TGF-β1 signalling has been seen in
the lung in several studies on COPD (for a review, see
[15]). Interestingly, TGF-β1 has also been shown to
regulate SLPI expression [16].
In healthy tissues, the oxygen tension is normally be-
tween 2.5 and 9%, corresponding to 20–70 mmHg oxy-
gen. During infections and inflammatory processes,
oxygen is consumed by inflammatory cells at the infec-
tious site, resulting in a hypoxic microenvironment with
oxygen levels below 1% (<8 mmHg) [17,18]. COPD and
CF patients have hypoxic areas in their lungs due to
mucus plugs in the bronchi, chronic inflammation and
tissue remodelling, resulting in shunting of blood from
poorly to well ventilated areas. It is known that hypoxia
increases the inflammatory function of inflammatory
cells [18], but very little is known about the effects of
hypoxia on the production of anti-proteases such as
SLPI in the airway epithelium.
The present study was performed to investigate the
impact of hypoxia on the secretion of SLPI by the re-
spiratory epithelium. The results show that SLPI is
down-regulated in bronchial epithelial cells in response
to hypoxia, and that this is mediated via a TGF-β1-
dependent mechanism.Methods
Chemicals and reagents
Recombinant human TGF-β1 was purchased from
Millipore (Darmstadt, Germany). Neutralizing monoclo-
nal antibody against TGF-β1 and corresponding isotype
IgG were obtained from R&D Systems (Minneapolis,
MN, USA).Cells and culturing conditions
Primary human bronchial epithelial cells from non-
smokers (3H Biomedical, Uppsala, Sweden) were grown in
BEGM medium supplemented with BEGM bullet kit
(Lonza, Basel, Switzerland) in poly-L-lysine-coated flasks
(Sigma, St. Louis, MO, USA). The cells were seeded in 24-
well plates (Sigma) coated with PurCol® (Advanced
BioMatrix, San Diego, CA, USA) (1:100 v/v in H2O). Cells
were grown until they were confluent and then incubated
for 72 h with or without different stimuli under normoxia
(21% O2, 5% CO2) or hypoxia (1% O2, 5% CO2). Hypoxic
incubation was performed in a C-Chamber (BioSpherix,
Lacona, NY, USA). After 48 h of incubation, the medium
was replaced with fresh medium including stimuli. This
medium had been pre-incubated in the cell incubator
under hypoxic or normoxic conditions. At the end of the
incubation period, the cell medium was collected and
stored at −80°C until analysis.
For the growth of air liquid interface (ALI) cell cultures,
Transwell® inserts in a 12-well plate were coated with
300 μl PurCol (1:100 v/v in H2O) for 20 min. Primary hu-
man bronchial epithelial cells were thereafter seeded onto
the inserts and maintained in BEGM medium in sub-
immersed cultures. When confluence was reached, the ap-
ical medium was removed and the baso-lateral medium
was replaced by ALI medium, consisting of one part
BEGM medium supplemented with BEGM bullet kit and
3 mg/ml BSA (Sigma), and one part D-MEM (Invitrogen,
Walthem, MA, USA) supplemented with 1 mM sodium
pyruvate MEM, 2 mM L-glutamine and non-essential
amino acids (all from Invitrogen). The cell medium was
thereafter changed at least 5 times/week. After 3–4 weeks
in ALI culture, the cells were incubated at 21% or 1% O2
as above. Hypoxic incubation of the ALI cultures was per-
formed with a glove box, InvivO2 Hypoxia 400 worksta-
tion (Ruskinn Technology Ltd, Bridgend, UK), to allow
work under hypoxic conditions. After 48 h of incubation,
the baso-lateral medium was changed and the apical sur-
faces were rinsed with PBS to remove excess mucus and
pre-formed peptides. Incubation was terminated after 72 h
by rinsing the apical surfaces with 100 μl 10 mM Tris buf-
fer with 5 mM glucose. The rinsing fluids were stored at
−80°C until analysis.
SLPI detection
SLPI was detected in cell medium supernatants and rins-
ing fluids with ELISA (R&D Systems) according to the
manufacturer’s protocol. As the volumes of the medium
and rinsing fluids were known, the total amounts of SLPI
released apically and baso-laterally could be compared.
RNA isolation and real-time PCR
Total RNA was isolated from primary human bronchial



































Figure 1 Hypoxia reduces SLPI expression in differentiated
bronchial epithelial cells. SLPI concentrations in the cell medium
(A) and rinsing fluid (B) from air liquid interface cultures incubated
at 21% or 1% O2. The figure shows means and SEM for at least 3
independent experiments.
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Qiagen (Hilden, Germany). The optical density ratio (OD
260 nm/OD 280 nm) of RNA was always greater than
1.95. Reverse transcription was performed according to
the manufacturer’s instructions on 1 μg total RNA using
an iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules, CA,
USA). RT-PCR was then used to quantify TGF-β1 and
SLPI mRNA expression with primer pairs from OriGene
Technologies (Rockville, MD, USA). Data were normal-
ized to succinate dehydrogenase complex subunit A. This
was chosen as internal standard based on analyses of the
expression of a panel of 7 genes commonly used for
normalization under hypoxic conditions (data not shown).
Expression was analysed using the iTaq™ Universal SYBR®
Green Supermix (Bio-Rad). Amplification was performed
at 55°C for 40 cycles in an iCycler Thermal Cycler (Bio-
Rad) and data were analysed using iCycler iQ Optical
System Software (Bio-Rad).
Neutrophil elastase activity assay
Neutrophil elastase activity was analysed with the chromo-
genic substrate N-methoxysuccinyl-Ala-Ala-Pro-Val p-
nitroanilide (Sigma). The baso-lateral cell medium from
ALI-cultures was diluted 1:4 in HEPES buffer (0.1 M
HEPES pH 7.5 + 0.5 M NaCl). Fresh cell medium was used
as a control. Equal amounts of diluted cell medium and
0.05 U/ml neutrophil elastase in HEPES buffer (40 μl
each) (Sigma, St. Louis, MO, USA) were mixed in a 96-
well plate. Samples were incubated at room temperature
for 20 min. To each well, 100 μl of 0.2 mM N-methoxy-
succinyl-Ala-Ala-Pro-Val p-nitroanilide in HEPES buffer
was added. The plate was incubated at room temperature,
and the absorbance was determined at 405 nm at different
time points.
Statistical analysis
Statistical calculations were performed using Student’s
T-test or one-way ANOVA. Differences were considered
statistically significant at p < 0.05.
Results
SLPI expression in bronchial epithelial cells is reduced
in response to hypoxia
In order to study the effects of hypoxia on the secretion of
SLPI in the airways, primary human bronchial epithelial
cells were grown in ALI cultures. Under these conditions,
cells differentiate to form a ciliated epithelium with mucus
production similar to the in vivo airway epithelium. The
differentiated cell cultures were incubated at 21% or 1%
O2 for 72 h, after which the cell medium was collected,
and the apical surfaces were rinsed to collect the pericili-
ary liquid (PCL) including secreted proteins and peptides.
Cells grown under hypoxic conditions were adherent and
could not be morphologically distinguished fromnormoxic cells with light microscopy. The SLPI content in
medium and rinsing fluids was analysed with ELISA. SLPI
was mostly released into the baso-lateral medium (349 ±
25 ng/ml) compared to the rinsing fluid (53 ± 12 ng/ml)
(Figure 1). However, if it is assumed that the depth of the
PCL was 5 μm [19], the apical SLPI levels in the PCL
would have been much higher at approximately 8 μg/ml,
which is in good agreement with in vivo data [20]. SLPI
concentrations were significantly reduced in both com-
partments in response to hypoxia (Figure 1).
We next investigated the effects of hypoxia on SLPI ex-
pression in non-differentiated primary bronchial epithelial
cells grown in sub-immersed cultures. These cells were in-
cubated at 21% or 1% O2, and SLPI concentrations in the
cell medium were analysed after 72 h of incubation. SLPI
levels were found to be reduced in cells grown under hyp-
oxic conditions (Figure 2A), in line with the data from ALI-
cultures. Cells were also harvested and analysed for mRNA
expression using RT-PCR. The results showed that SLPI
mRNA is down-regulated in response to hypoxia


































Figure 2 SLPI expression in bronchial epithelial cells is reduced
in response to hypoxia. A) SLPI concentrations in cell medium
from primary human bronchial epithelial cells grown under normal
oxygenation (21% O2) or under hypoxic conditions (1% O2) (n = 5).
B) SLPI mRNA levels from bronchial epithelial cells incubated at 21%
or 1% O2. The values of fold change were calculated by normalizing
to the data from the 21% O2 samples. The figure shows means and












































Figure 3 SLPI expression is down regulated by TGF-β1. SLPI
concentrations in the cell medium from human bronchial epithelial
cells stimulated with TGF-β1 (A), or in the absence or presence of
1 ng/ml TGF-β1 (B). The figure shows means and SEM of at least
three independent experiments.
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not a consequence of an overall reduction in metabolism.
Since the response to hypoxia was similar in both cell
culturing systems, we continued to work with non-
differentiated cells to facilitate the studies of underlying
mechanisms.
Hypoxia regulates SLPI expression via TGF-β1 signaling
TGF-β1 is a growth factor that has been shown to down-
regulate SLPI [16]. To confirm that SLPI can be regulated
by TGF-β1 in the airways, bronchial epithelial cells were
stimulated for 72 h with different concentrations of TGF-
β1. SLPI concentrations in the cell medium were there-
after detected with ELISA. SLPI expression decreased with
increasing TGF-β1 concentrations (Figure 3A), and the
down-regulation of SLPI expression was more pro-
nounced over time (Figure 3B).In order to analyse the effect of hypoxia on TGF-β1 ex-
pression, RNA was isolated from cells grown in 21% and
1% oxygen, and the mRNA expression of TGF-β1 and
SLPI was subsequently quantified using RT-PCR. TGF-β1
mRNA was significantly up-regulated in response to hyp-
oxia (Figure 4A). Cells were then incubated in 21% or 1%
O2, in the presence of a neutralizing antibody against
TGF-β1. An isotype control antibody was used in parallel.
Compared to the control antibody, SLPI expression in
hypoxic cells was increased in response to anti-TGF-β1
(Figure 4B). Taken together, these results suggest that hyp-
oxia down-regulates SLPI expression via up-regulation of
TGF-β1 in bronchial epithelial cells.
Medium from hypoxic cells is less potent in inhibiting
neutrophil elastase activity
To investigate whether hypoxia affects the anti-protease
property of the airway epithelium, baso-lateral cell medium
from ALI cells stimulated with 21% or 1% oxygen was incu-
bated with neutrophil elastase. Elastase activity was thereafter
measured using a chromogenic assay. The results show a








































Figure 4 Expression of TGF-β1 and SLPI in response to hypoxia.
A) Expression of TGF-β1 mRNA in bronchial epithelial cells cultured in
21% or 1% oxygen. The fold changes were calculated by normalizing
to data from the 21% O2 samples (n = 4). B) SLPI concentrations in the
cell medium from bronchial epithelial cells incubated at 21% or 1% O2
in the presence of a neutralizing antibody against TGF-β1 (50 μg/ml) or
an isotype control antibody (n = 5).
Normoxia
SLPI 
Figure 5 Schematic model of hypoxia-driven SLPI expression. During
SLPI, both apically and baso-laterally. When the oxygen concentrations dec
down-regulates SLPI production.
Påhlman et al. BMC Pulmonary Medicine  (2015) 15:19 Page 5 of 7and hypoxic cell medium, where medium from normoxic
cells inhibited elastase activity more efficiently (Additional
file 1: Figure S1). These results indicate that hypoxia reduces
the anti-protease potential of the airway epithelium.
Discussion
We have demonstrated a mechanism whereby SLPI is
down-regulated in the airway epithelium in response to
hypoxia (Figure 5). Under normal conditions, SLPI is
constitutively expressed in epithelial cells. When oxygen
is limited, hypoxia promotes up-regulation of TGF-β1,
which in turn down-regulates SLPI.
When tissues are exposed to hypoxia, cells respond by up-
regulating a number of genes, mainly through the hypoxia-
inducible factor (HIF) pathways. HIFs are heterodimeric
transcription factors that are rapidly degraded under condi-
tions of normal oxygenation, but are stabilized and accumu-
late during hypoxia [21]. It has been reported that HIF-1α is
up-regulated in the airways of patients with COPD and
chronic bronchitis [22,23]. Although HIF-1α has been
shown to regulate the TGF-β1 gene in mesenchymal stem
cells [24], further studies are needed to investigate whether
TGF-β1 and SLPI in the airways are regulated via HIF-1α or
other hypoxia-driven pathways under hypoxic conditions.
However, the increase in HIF-1α in the airways of COPD
patients indicates that they have hypoxic regions in their
lungs. Studies using direct oxygen measurements in the
lungs of CF patients have demonstrated a hypoxic environ-
ment in the airway mucus, with mean oxygen levels as low
as 2.5 mmHg [25]. SLPI concentrations in the airways of
COPD and CF patients are reduced during bacterial exacer-
bation, and it has been postulated that the mechanism be-
hind this observation involves proteolytic cleavage of the
protein by neutrophil elastase [26-29]. Here, we propose a
complementary mechanism whereby aggravated hypoxiaHypoxia 
SLPI 
TGF- 1 
normal oxygenation, the bronchial epithelium constitutively secretes
rease, the epithelium increases its expression of TGF-β1, which in turn
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centration. Interestingly, it has also been reported that
down-regulation of SLPI in COPD involves TGF-β1 signal-
ling [30], which supports our model.
Conflicting data have been reported regarding the effects
of hypoxia on TGF-β1 secretion. Boussat and co-workers
found no change in TGF-β1 protein levels in the cell
medium from pulmonary epithelial cells grown under hyp-
oxic conditions [31], whereas others have reported an in-
crease in TGF-β1 protein in response to hypoxia [24]. Our
data show that neutralization of TGF-β1 with an antibody
increases SLPI levels in hypoxic cells, suggesting that TGF-
β1 concentrations are elevated under hypoxic conditions.
Interestingly, Ambalavanan and co-workers showed that
mice exposed to hypoxia exhibit an increased level of active
TGF-β1 in their lungs, whereas total TGF-β1 concentrations
were unchanged compared with controls [32]. This observa-
tion may explain the conflicting results on TGF-β1 levels in
response to hypoxia.
SLPI was originally identified as a physiologically important
inhibitor of neutrophil elastase and other proteases.
Dysregulation of SLPI levels in the lungs of COPD and CF
patients would therefore render them more vulnerable to
damage caused by the inflammatory response. It is now
known that the protein also has antimicrobial and immuno-
modulatory functions. SLPI has been shown to be effective
against a number of gram-positive and gram-negative bac-
teria, including species common in the CF and COPD re-
spiratory tract, such as Pseudomonas aeruginosa and
Staphylococcus aureus [3,33]. Furthermore, SLPI can inhibit
the inflammatory response by binding to lipopolysaccharide,
thereby preventing macrophage activation [34]. This has
been demonstrated in vivo, where SLPI-deficient mice chal-
lenged with lipopolysaccharide showed higher mortality and
higher IL-6 expression than wildtype mice [35]. Moreover,
clinical studies in which CF patients were given aerosolized
recombinant SLPI have demonstrated that SLPI not only
neutralizes neutrophil elastase activity, but also has an immu-
noregulatory effect, reducing IL-8 and neutrophil levels in
the epithelial lining fluid [36,37]. This multifunctional role of
SLPI makes it interesting from a therapeutic point of view,
as altering this system could potentially reduce over-
exaggerated proteolytic activity in inflammatory lung diseases
such as COPD and CF, modulate the inflammatory response,
and protect these patients from bacterial infections [38].
A limitation of the present study is that only epithelial
cells were studied. Fibroblasts, endothelial cells and inflam-
matory cells were not studied, and their contributions to
SLPI regulation in an in vivo setting are therefore unknown.
Moreover, the experiments were carried out under non-
inflammatory conditions. Further studies are thus needed to
evaluate how hypoxia effects SLPI expression in the pres-
ence of normal airway microbiota, airway pathogens or
other inflammatory stimuli.Conclusion
In conclusion, the present study demonstrates that SLPI is
down-regulated in the bronchial epithelium during hyp-
oxia. These findings may help explain the pathogenesis of
inflammatory lung diseases, and provide a potential target
for the treatment and prevention of exacerbation in these
patients.
Additional file
Additional file 1: Figure S1. Cell medium from hypoxic cells has
reduced capacity to neutralize neutrophil elastase. Cell medium from
air-liquid interface cultures exposed to normoxia or hypoxia were
incubated with neutrophil elastase, and the elastase activity in the
samples was thereafter analysed with a chromogenic assay. The figure
shows neutrophil elastase (NE) activity in the presence of normoxic or
hypoxic cell medium, compared to control medium (n = 6).
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